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48Background: In clinical stage IIIA non–small cell lung cancer, the role of surgical resection, particularly pneu-
monectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of
survival after postinduction surgical resection.
Methods: We retrospectively reviewed a prospectively collected database of 136 patients who underwent sur-
gical resection after induction chemotherapy (n ¼ 119) or chemoradiation (n ¼ 17) from June 1990 to January
2010.
Results:One hundred five lobectomies or bilobectomies and 31 pneumonectomies were performed. Therewas 1
perioperative death (pneumonectomy). Seventy-one patients had downstaging to N0 or N1 nodal status (52%).
There were 2 complete pathologic responses. Median follow-up was 42months (range, 0.69–136months). Over-
all 5-year survival for entire cohort was 33% (36% lobectomy, 22% pneumonectomy, P¼ .001). Patients with
pathologic downstaging to pN0 or pN1 had improved 5-year survival (45% vs 20%, P¼ .003). For patients with
pN0 or pN1 disease, survival after lobectomy was better than after pneumonectomy (48% vs 27%, P¼ .011). In
patients with residual N2 disease, there was no statistically significant survival difference between lobectomy
and pneumonectomy (5-year survival, 21% vs 19%; P ¼ .136). Multivariate analysis showed as independent
predictors of survival age (hazard ratio, 1.05; P ¼ .002), extent of resection (hazard ratio, 2.01; P ¼ .026),
and presence of residual pN2 (hazard ratio, 1.60; P ¼ .047).
Conclusions: After induction therapy for patients with clinical stage IIIA disease, both pneumonectomy and
lobectomy can be safely performed. Although survival after lobectomy is better, long-term survival can be ac-
complished after pneumonectomy for appropriately selected patients. Nodal downstaging is important determi-
nant of survival, particularly after lobectomy. (J Thorac Cardiovasc Surg 2011;141:48-58)Patients with clinical stage IIIA non–small cell lung cancer
(NSCLC) show a broad spectrum of disease.1-16 Although
the disease at this stage is defined mainly by the presence
of ipsilateral mediastinal nodal metastases, there is
significant variability in both the extent and bulk of nodal
involvement, as well as the size and extent of the primary
tumor. Accordingly, resectability rates after preoperative
therapy vary between 30% and 83%.1-19 Because of the
heterogeneity in disease presentation, there is reasonable
controversy regarding the optimal treatment approach for
these patients. Many have disputed the role of surgicale Division of Thoracic Surgery, Department of Cardiothoracic Surgery, New
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The Journal of Thoracic and Cardiovascular Surgeresection and consider that the best available evidence
supports concurrent chemoradiation alone as the standard
of care.7,11,14,20-25 In contrast, 2 small randomized trials
and several large retrospective series have suggested that
surgical resection after preoperative therapy may be
a better option for at least a subset of patients.1,3,4,6,8-
10,12,15,26 The precise role of surgical resection is not well
defined, however, especially for patients with residual
mediastinal nodal disease and those in whom
a pneumonectomy may be necessary.4,5,13,27 For the
purposes of this report, we retrospectively reviewed our
results in a selected subset of patients with clinically
staged N2 disease deemed resectable at presentation and
treated by induction therapy before surgical resection.
Our results reaffirm that sterilization of the mediastinal
nodes is a dominant determinant of survival. The data
also suggest that in this selected group of patients,
surgical resection may be a useful modality in
the presence of persistent nodal disease and that
pneumonectomy is associated with a significant reduction
in long-term survival, regardless of mediastinal nodal
downstaging.ry c January 2011
Abbreviations and Acronyms
CI ¼ confidence interval
CT ¼ computed tomography
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
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Study Design and Patient Selection
We conducted a retrospective review of a prospective lung cancer data-
base to select patients with clinical stage IIIA NSCLC treated by neoadju-
vant therapy followed by surgical resection. Patients were selected for
review if they hadmediastinal nodal metastases confirmed by either media-
stinoscopy or radiographic criteria (positron emission tomography [PET]
positive nodes at least 1.5 cm in size). Only patients with clearly resectable
disease were considered for induction therapy. Patients with multistation
mediastinal nodal disease were treated with preoperative intent only if
a complete surgical resection was deemed probable before induction ther-
apy. We excluded patients with contralateral nodal metastases (N3), extra-
nodal extension at mediastinoscopy, clinical T4 disease, or severe
cardiopulmonary impairment precluding surgical resection. Patients with
multistationmediastinal nodal disease deemed technically unresectable be-
fore preoperative therapy were also excluded. This study was approved by
the institutional review board of the NewYork Presbyterian Hospital–Weill
Cornell Medical Center. Informed consent was waived.
Clinical Staging
All patients underwent preoperative evaluation with a complete history
and physical examination, computed tomography (CT) of the chest and up-
per abdomen, a brain imaging study, and (since 2000) a fludeoxyglucose F
18 PET scan. A staging cervical mediastinoscopy was performed in 114
cases (84%). The remaining 22 patients were referred after neoadjuvant
therapy was started on the basis of clinical N2 disease determined from
nodal size on CT scan and nodal fludeoxyglucose F 18 uptake.
Neoadjuvant Therapy
One hundred nineteen patients received 2 to 3 cycles of induction che-
motherapy (platinum/taxane doublets, n ¼ 104) given every 3 weeks. The
remainder (n ¼ 17) received weekly chemotherapy with concurrent radia-
tion, with the radiation dose varying between 40 and 54 Gy.Clinical Response
Clinical responsewas determined by restaging CTand PET scans done 2
to 4 weeks after the last preoperative treatment. Clinical response (com-
plete response, partial response, minimal response, stable disease, or dis-
ease progression) was determined by World Health Organization criteria
before 2000 and subsequently by Response Evaluation Criteria In Solid
Tumors (RECIST) criteria.28 Major clinical responses included complete
and partial responses, whereas patients with minimal response or stable dis-
ease were considered to have a minimal response. Restaging of the medi-
astinum by remediastinoscopy, endobronchial ultrasonography, or video-
assisted thoracoscopy was not performed.
Surgical Resection
All patients underwent resection through an open thoracotomy. After
the planned anatomic resection was completed, all patients underwent
a complete mediastinal lymph node dissection, including nodal stations
2, 4, 7, 8, and 9 for right-sided tumors and 4, 5, 6, 7, 8, and 9 for left-
sided tumors. A complete resection (R0) was defined as no residual grossThe Journal of Thoracic and Cor microscopic disease detected at the bronchial or vascular margins and no
residual disease in the mediastinum after nodal dissection. Incomplete re-
sections (R1 and R2) were defined as the presence of microscopic residual
tumor at the resected bronchial or vascular margins or residual unresectable
nodal disease.
Data Collection and Statistical Considerations
Hospital and office records were reviewed for each patient for demo-
graphic and clinical data including age, sex, pretreatment clinical staging,
induction therapy, surgical pathology, and adjuvant therapy. Data were ex-
pressed as medians or percentages. Bilobectomies and sleeve lobectomies
were grouped with lobectomies for statistical analysis. To assess the asso-
ciation between categoric and outcome variables, c2 analyses were used.
The nonparametric Mann–Whitney U test was used to assess the associa-
tion between categoric variables and continuous outcomes. Median
follow-up time was calculated on the basis of surviving patients. Overall
survival and disease-free survival were estimated with the Kaplan–Meier
method from the date of surgery because the date of initiation of preoper-
ative therapy was not consistently available. Overall survival was estimated
from the date of surgical resection until death from any cause or the date of
last follow-up. Disease-free survival was estimated from the date of surgi-
cal resection until tumor recurrence or death from any cause. Comparisons
of survival distributions between clinical factors were conducted with the
log-rank test. All P values were 2-sided. Cox proportional hazards regres-
sion analysis was used to identify univariate predictors factors of survival
that were thought to be of clinical significance a priori. All univariate pre-
dictors with a P value of .2 or less were entered into the multivariate model.
The variables considered in the model included the following: age, sex,
histologic type, clinical and pathologic T size, clinical N size, clinical re-
sponse to therapy, residual pathologic nodal status, and extent of resection.
Because there were 80 events (deaths) and 56 nonevents (live patients), the
multivariate input was limited to no more than 6 factors. The statistical
package used was SPSS statistical software version 17.0 (SPSS Inc, an
IBM Company, Chicago, Ill).
RESULTS
Patient Characteristics
One hundred thirty-six patients underwent surgical resec-
tion after induction therapy for clinical stage IIIA NSCLC
between June 1990 and January 2010. Their median age
was 64.0 years (range, 37–84 years), and most were women
(n ¼ 79). Patient demographic data, clinical staging infor-
mation, and cell types are shown in Table 1.
Pretreatment Staging
Mediastinoscopy was performed in 114 patients (84%),
95 of whom (83%) had single-station mediastinal disease.
The median number of sampled nodal stations at mediasti-
noscopy was 3 (range, 2–4). Patients in whom N2 disease
was radiographically diagnosed without mediastinoscopy
had significantly larger median primary tumor size than
those with N2 disease detected by mediastinoscopy
(5.20 cm vs 3.40 cm, P¼ .002) and significantly larger me-
dian mediastinal nodal size (2.15 cm vs 1.5 cm, P<.001)
but comparable survival (data not shown).
Clinical Response
Sixty-one patients (45%) had a major clinical response
(4 complete responses, 57 partial responses). Seventy-fiveardiovascular Surgery c Volume 141, Number 1 49
TABLE 1. Patient characteristics (n ¼ 136)
Age (y, median and range) 64.0 (37–84)
Sex (no. female) 79 (58%)
Comorbidities (no.)
Chronic obstructive pulmonary disease 50 (37%)
Coronary artery disease 11 (8%)
Hypertension 50 (37%)
Diabetes mellitus 14 (10%)
Smoking history 110 (81%)
Radiologic characteristics
Clinical T size (cm, median, n ¼ 123) 3.6
Clinical N size (cm, median, n ¼ 116) 1.7
Positron emission tomography with or without
computed tomography (no. since 2000)
102 (75%)
Mediastinoscopy (no.) 114 (84%)
Single station 95 (70%)
Multiple station 12 (9%)
Unknown 7 (5%)
Not performed 22 (16%)
cT status (no.)
cT1 38 (28%)
cT2 85 (62%)
cT3 13 (10%)
Induction therapy (no.)
Chemotherapy 119 (88%)
Chemoradiation 17 (12%)
Clinical response (no.)
Complete 4 (3%)
Partial 57 (42%)
Minimal 21 (15%)
Stable disease 54 (40%)
Cell type (no.)
Squamous 26 (19%)
Adenocarcinoma or bronchoalveolar carcinoma 89 (65%)
Other 21 (15%)
TABLE 2. Surgical characteristics (n ¼ 136)
Characteristic No. %
Procedure
Lobectomy 93 68%
Sleeve resection (right upper lobe) 1 1%
Bilobectomy 11 8%
Pneumonectomy 31 23%
Right 13
Left 18
Completeness of resection
R0 131 96.3%
R1 or R2 5 3.6%
In-hospital mortality 1 0.7%
TABLE 3. Postsurgical pathology (n ¼ 136)
Pathologic response
Complete response 2 (1.4%)
Total nodes examined per patient (median and range) 17 (1–42)
Positive nodes pN2 per patient (median and range) 2 (1–22)
Residual pN2 disease 65 (48%)
Multilevel residual pN2 disease 16 (12%)
Pathologic stage*
0 2 (1.4%)
IA 17 (12.5%)
IB 14 (10.3%)
IIA 14 (10.3%)
IIB 16 (11.8%)
IIIA 63 (46.3%)
IIIB 10 (7.4%)
Data represent numbers and percentages of patients except as noted. *Per Greene FL,
PageDL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer stagingman-
ual. 6th ed. New York: Springer; 2002.
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response (Table 1).
Surgical Treatment
Lobectomy was performed in 93 patients, bilobectomy in
11 patients, and sleeve lobectomy in 1 patient. Thirty-one
patients underwent pneumonectomy (23%). R0 resection
was achieved in most cases (n ¼ 131, 96.3%; Table 2).
There were no in-hospital deaths among the lobectomy, bi-
lobectomy, and sleeve lobectomy patients. There was 1
in-hospital death in the pneumonectomy group (3.2%);
death was due to adult respiratory distress syndrome after
a right pneumonectomy.
Postsurgical Pathology
Postsurgical staging is shown in Table 3. The median
number of resected lymph nodes was 17, and the median
number of positive nodes was 2 (range, 1–22). A complete
pathologic response was observed in 2 patients (1.4%). Re-50 The Journal of Thoracic and Cardiovascular Surgesidual N2 disease was present in 65 patients (48%),
whereas 71 patients (52%) had downstaging to N0 or N1
disease. Multilevel residual N2 disease was present in 16
patients (12%; Table 3). Although patients with a major
clinical response were significantly more likely to have
downstaging of disease in the mediastinum (42/61, 69%),
39% of patients with stable disease or minimal response
also had sterilization of the mediastinal nodes (29/75,
P ¼ .001). There was a nonstatistically significant trend to-
ward a higher probability of mediastinal nodal downstaging
in patients treated by lobectomy than in those treated by
pneumonectomy (lobectomy 56%, 59/105, pneumonec-
tomy 39%, 12/31, P ¼ .104). Median pathologic tumor
size was significantly larger in patients undergoing pneu-
monectomy than in those undergoing lobectomy (4.3 cm
vs. 2.5 cm, P<.001).
Adjuvant Therapy
Half of the patients received no adjuvant therapy (n¼ 68,
50%). The remainder received either chemotherapy
(n ¼ 11, 8%), radiation (n ¼ 26, 19%), or both (n ¼ 14,
10%). Radiation or chemoradiation were typically givenry c January 2011
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tion of the medical oncologist. The adjuvant therapies for 17
patients (13%) are unknown.
Survival Analysis
Overall and disease-free survivals. Median follow-up for
surviving patients was 42 months (range, 0.69–136
months). Median and 5-year overall survivals for the entire
cohort were 31.8 months (95% confidence interval [CI],
25.6–38.0 months) and 33.4% (95% CI, 33.3%–33.5%),
respectively. Median and 5-year disease-free survivals
were 19.6 months (95% CI, 15.6–23.8 months) and
27.8% (95% CI, 19.0%–36.6%), respectively.
Survival and response. Five-year overall survival was bet-
ter among patients with a major clinical response (complete
response or partial response) than among all others (mini-
mal response or stable disease, 43.8% vs 25.2%;
P ¼ .024). Patients with pathologic downstaging of disease
to ypN0 or ypN1 had a significant improvement in 5-year
overall survival relative to those with ypN2 disease (45%
vs 20%, P ¼ .003; Figure 1). Among patients with down-
staging to ypN0 or ypN1, there was no significant difference
in survival noted between those with ypN0 disease and
those with ypN1 (47% vs 42%, P ¼ .450). In the subset
of patients with residual N2 disease, the level of ypN2 dis-
ease (multilevel vs single level) was not a significant predic-FIGURE 1. Overall survival, downstaged disease (ypN0 or ypN1) versus
disease not downstaged (ypN2).
The Journal of Thoracic and Ctor of survival (hazard ratio, 1.12; 95% CI, 0.550–2.275;
P¼ .756). Similarly, there was no difference in survival ac-
cording to the level of cN2 disease determined at mediasti-
noscopy (38% vs 32%, P ¼ .500).
Extent of resection and survival. Survival was signifi-
cantly higher among patients treated by lobectomy than
among those treated by pneumonectomy (36% vs 22%,
P ¼ .001; Figure 2). As shown in Figure 3, A, patients
with downstaging to ypN0 or ypN1 had a 5-year survival
of 48% after lobectomy and a 5-year survival of 27% after
pneumonectomy (P ¼ .01). There was no significant differ-
ence in 5-year survival between patients with residual N2
disease treated by lobectomy and those treated by pneumo-
nectomy (21% vs 19%, P ¼ .136; Figure 3, B).Recurrence and Death
Disease recurred in 75 patients (55%): 56 patients after
lobectomy (53%) and 19 patients after pneumonectomy
(62%). Information about the site of first recurrence was
available in 64 cases. The first site of recurrence was sys-
temic in 50 patients (78%): 94% (16/17) after pneumonec-
tomy and 72% (34/47) after lobectomy. For the whole
cohort of 135 patients who survived hospitalization, local
recurrence alone was the site of first recurrence in 13 pa-
tients (12%) after lobectomy and in 1 patient (10%) afterFIGURE 2. Overall survival, pneumonectomy versus lobectomy.
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FIGURE 3. A, Overall survival, pneumonectomy versus lobectomy in patients with downstaged disease (ypN0 or ypN1). B, Overall survival, pneumonec-
tomy versus lobectomy in patients with disease not downstaged (ypN2).
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lated in both the lobectomy and pneumonectomy groups
(44.8% and 54.8%, respectively). Non–cancer related
deaths were 11% in the lobectomy group and 16% in the
pneumonectomy group (P¼ .122). Median times to disease
recurrence were 8.00 months (95% CI, 7.96–14.24 months)
after pneumonectomy and 23.20 months (95% CI, 15.40–
30.96 months) after lobectomy (P ¼ .001; Figure 4).Univariate Analysis
The effects of several factors, including age, sex, clinical
response, histologic type, clinical Tand N size, pathologic T
size, residual pN2 status, and extent of resection, on overall
survival were tested with Cox regression analysis (Table 4).
Five univariate predictors of survival were identified: age,
clinical response, pathologic T size, the presence of residual
N2 disease, and extent of resection (Table 4).Multivariate Analysis
Univariate predictors with P values of at least .2 were en-
tered into a multivariate model. This model identified extent
of resection (P ¼ .026) as an independent predictor of poor
survival, along with age (P ¼ .002) and the presence of re-
sidual pN2 disease (P ¼ .047) (Table 5). A multivariate
analysis examining the impact of the same factors on52 The Journal of Thoracic and Cardiovascular Surgedisease-free survival yielded the same results (data not
shown).DISCUSSION
This series provides supportive evidence that sterilization
of the mediastinum is an important predictor of good out-
come. The data also suggest that although survival is un-
doubtedly best in patients with downstaged disease, the
presence of persistent N2 disease should not preclude con-
sideration of surgical resection in patients for whom a lobec-
tomy is planned and an R0 resection is anticipated. In such
circumstances, the expected 5-year survival is approximately
20%. The overall survival reported here for patients with
ypN2 disease is generally similar to values previously re-
ported by several randomized and phase II trials, as well as
single-institution case series.1,5-7,9,10,12,14,15,17-19 In a phase
II study, the Swiss Group for Clinical Cancer Research
reported a 5-year survival of 16% for patients with
persistent N2 disease after 3 cycles of docetaxel and
cisplatin.6,19 Similarly, patients with residual ypN1 to ypN3
disease after induction chemoradiation in the surgical arm
of the Intergroup trial 0139 and those with ypN1 to ypN3
disease after induction chemotherapy in the phase II
Spanish Lung Cancer Group 9001 trials had 5-year
survivals of 24% and 18%, respectively.7,12 Severalry c January 2011
FIGURE 4. Disease-free survival, pneumonectomy versus lobectomy.
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survivals of 20% to 27% among patients with persistent
N2 disease after induction therapy.4,8,10,13,17 Whether
similar results in patients with ypN2 disease could be
achievable by chemoradiation is in our view debatable.20-22
A randomized trial by Dillman and colleagues comparing
sequential chemoradiation to radiation alone in patients
with clinical IIIA disease reported a 5-year survival of
17% in the chemoradiation arm of the trial.21,22 AlthoughTABLE 4. Univariate predictors of survival
Variable Subgroup B
Age 0.028
Sex Male
Female 0.02
Clinical response Stable or minimal
Complete or partial 0.520
Histologic type Nonsquamous
Squamous 0.382
cT size 0.042
cN size 0.085
pT size 0.113
pN status pN0 or pN1
pN2 0.651
Extent of resection Lobectomy
Pneumonectomy 0.783
The Journal of Thoracic and Cthese results are sometimes compared with surgical results,
only 50% of patients in that trial were surgically staged.
Furthermore, the reported 17% 5-year survival after
chemoradiation reflects the aggregate survival of patients
with and without mediastinal nodal downstaging. We
therefore believe that the case against surgical resection in
the face of persistent nodal metastases is not conclusive
and requires further evaluation. In the meantime, the
decision to proceed with surgical resection should be an
individual determination that is based on age, performance
status, comorbidities, the likelihood of achieving an R0
resection (especially if by lobectomy), and in no small
measure, the availability of viable treatment alternatives.
Regardless, the larger question is whether surgical resec-
tion is ever appropriate for patients with cN2 disease. Two
large randomized trials have suggested that postinduction
surgical resection (specifically resection after chemoradia-
tion) adds little or no benefit beyond that achieved by che-
moradiation alone.7,15 Even in these trials, however, either
patient selection criteria or insufficient accrual may limit
generalization of the results to all patients with N2
disease. For example, the randomized European
Organization for Research and Treatment of Cancer
(EORTC) trial reported by van Meerbeeck and
associates15 included patients with ‘‘unresectable’’ disease,
and the reported resectability rate in the surgical arm of that
trial was accordingly only 50%.15 This differs from our re-
port in that we only considered patients with clearly resect-
able disease for treatment with preoperative intent. The
intergroup randomized trial reported by Albain and col-
leagues7 showed no difference in the primary end point of
overall survival between patients treated by chemoradio-
therapy followed by surgery and those treated by chemora-
diation alone. The study was prematurely closed because of
poor accrual, however, having failed to accrue the sample
size required to demonstrate the 10% survival benefit after
surgical resection postulated by the investigators.Hazard ratio 95% Confidence interval P value
1.03 1.01–1.05 .021
1.00
1.02 0.82–1.27 .859
1.00
0.59 0.38–0.94 .026
1.00
1.47 0.87–2.48 .155
1.04 0.92–1.18 .499
1.09 0.70–1.70 .709
1.12 1.03–1.22 .007
1.00
1.93 1.24–3.01 .004
1.00
2.19 1.35–3.56 .002
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TABLE 5. Multivariate predictors of survival
Variable Subgroup B Hazard ratio 95% Confidence interval P value
Age 0.047 1.05 1.02–1.08 .002
Clinical response Stable or minimal 1.000
Complete or partial 0.468 0.63 0.37–1.06 .082
Histologic type Nonsquamous 1.00
Squamous 0.439 1.55 0.80–3.00 .193
pT size 0.033 1.034 0.94–1.14 .488
pN status pN0 or pN1 1.00
pN2 0.469 1.60 1.01–2.54 .047
Extent of resection Lobectomy 1.00
Pneumonectomy 0.699 2.01 1.09–3.71 .026
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which was performed in nearly a third of those patients,
may have negated any potential benefit from surgical resec-
tion. It is now generally accepted that such a high perioper-
ative mortality after postinduction pneumonectomy may
not reflect operative outcomes in specialized surgical
centers.18,29 The question of surgical restaging the
mediastinum by remediastinoscopy, video-assisted thoraco-
scopy, or endobronchial ultrasonography cannot be an-
swered by our data. Advocates of such measures consider
that resection in the face of persistent nodal disease in the
mediastinum is not warranted, a view to which we do not
subscribe in the absence of more definitive evidence.
A second controversial aspect in surgical treatment is the
extent of parenchymal resection. Several studies have re-
ported that in-hospital mortality after pneumonectomy is
quite high, and it may be prohibitive after right pneumonec-
tomy.13 Martin and coworkers13 reported on 97 patients
treated by pneumonectomy after preoperative chemother-
apy. Whereas in-hospital mortality was 11% overall, it
was a much higher 24% after right pneumonectomy. Simi-
larly, and as noted previously, in-hospital mortality after
pneumonectomy was 26% in the surgical arm of the Inter-
group 0139 trial.7 The same study showed no benefit in sur-
vival if patients were treated by chemotherapy or
radiotherapy followed by pneumonectomy relative to
a matched group of patients in the nonsurgical arm of the
study. It is certainly possible that a perioperative mortality
of 26%may have disguised any possible therapeutic benefit
after resection, and some have advocated that sleeve lobec-
tomy should be strongly considered as an alternative surgi-
cal option whenever possible. Some have also suggested
that pneumonectomy is a disease entity unto itself, with
a profound impact on cardiorespiratory physiology leading
to decreased overall survival.30 In our data set, despite a low
in-hospital mortality, pneumonectomy was associated with
both worse overall survival and worse disease-free survival
relative to lobectomy, regardless of mediastinal downstag-
ing. This finding suggests that the notion that survival after
pneumonectomy may be improved if in-hospital mortality
is reduced to acceptable levels may be incorrect. The poor54 The Journal of Thoracic and Cardiovascular Surgeoutcomes after pneumonectomy are also not likely to be
averted if a sleeve lobectomy is done instead. In this study,
patients undergoing pneumonectomy had a higher tumor
burden, as shown by larger primary tumor size and bulkier
nodal disease, factors that may have precluded lung-sparing
resections.
Finally, our study does not attempt to answer the question
regarding the optimal preoperative therapy. We can, how-
ever, make several observations that in the aggregate may
argue against adding radiation to the preoperative regimen,
at least for the patient population described in this work.
First, the 52% rate of sterilization of the mediastinum in
our study compares favorably with that reported after pre-
operative chemoradiotherapy in the Intergroup trial.7 Sec-
ond, 12% of patients after lobectomy and 10% of
patients after pneumonectomy had isolated local recurrence
as the first site of relapse, whereas most recurrences (78%)
were systemic in nature. This probably argues that the addi-
tion of another modality of local therapy may simply in-
crease morbidity without translating into a major survival
benefit. A recent randomized trial by the German Lung
Cancer Cooperative Group showed that in comparison to
preoperative chemotherapy alone, preoperative chemother-
apy and radiation led to a higher complete pathologic re-
sponse rate, but at the expense of higher morbidity and
without an ultimate improvement in survival.14
Despite the prospective acquisition of the data, this study
is limited by its retrospective nature. Therefore, hidden se-
lection biases cannot be reasonably excluded. The study
also extended through at least 2 decades, raising some con-
cern regarding differences in treatment strategies and out-
comes with time. Nonetheless, the surgical strategy of
anatomic parenchymal resection and radical mediastinal
nodal dissection and the chemotherapeutic strategy of a plat-
inum-based doublet regimen have remained relatively sta-
ble through time within our group, thus diminishing the
impact of that concern. Finally, some of our findings have
to be considered with caution because of our small sample
size. For example, the lack of a significant difference in sur-
vival between patients with single-level versus multilevel
nodal disease is likely a reflection of our inability to detectry c January 2011
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tistical analysis by the small sample size.
In conclusion, this retrospective analysis of surgical re-
section after induction therapy for clinical stage IIIA
NSCLC demonstrates that surgical resection can be per-
formed safely with long-term survival for appropriate pa-
tients. Our study suggests that the ideal patient who
would benefit maximally from surgical resection after in-
duction therapy for clinical IIIA disease is young, requires
only lobectomy for complete resection, and has evidence
of mediastinal downstaging. Our analysis, however, has in-
sufficient data to suggest that patients with residual N2 dis-
ease after induction therapy should be excluded from
surgical resection. Five-year survival even for nonideal pa-
tients, such as patients who undergo pneumonectomy with
residual N2 disease, is approximately 20%, which may be
acceptable for appropriate patients as long as operativemor-
tality can be kept low.References
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Dr Gail E. Darling (Toronto, Ontario, Canada). Dr Paul, I
thank you and your coauthors for providing me with the manu-
script and your presentation in advance of the meeting. I compli-
ment you for tackling this topic and also for your very
commendable operative mortality, which is particularly outstand-
ing for this group of patients.ardiovascular Surgery c Volume 141, Number 1 55
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SDuring the study interval, you found 136 patients with N2 dis-
ease who underwent surgical resection after induction. How many
patients with N2 disease were evaluated in your center, and how
did you select patients for surgery?
Dr Paul.During that interval, probably around 450 patients had
positive results of mediastinoscopy; however, those included pa-
tients who had likely stage III disease and some patients who prob-
ably underwent a mediastinoscopy for diagnosis as well. Because
we are a referral center, we also get patients sent to us who have
had positive results of mediastinoscopy at an outside institution
and are coming in after induction therapy to undergo resection.
So it’s a fairly low number of patients who actually finally made
it to surgery. In our series, it was probably around 20% to 25%.
Our selection criteria are basically that patients must have good
functional status and the cardiopulmonary ability to tolerate resec-
tion and also must have at least stable disease in response to induc-
tion therapy.
Dr Darling. Thank you. I noticed that 11% of patients had mul-
tiple-station N2 disease.
Dr Paul. Correct.
Dr Darling. So you did not exclude those patients from consid-
eration for surgery?
Dr Paul. We did not.
Dr Darling. Among patients who did not have confirmation of
N2 disease before induction, was there any evidence of tumor re-
gression on final pathologic examination? We know that 40% of
enlarged nodes on CT scan are actually benign, and 20% to 25%
of hot nodes on PET scan are actually benign. So how can you
be sure that those 22 who didn’t actually undergo invasive staging
before induction really did have N2 disease?
Dr Paul. Of those 22 patients, 11 patients had either N1 or N2
disease in the final pathologic specimen, so about 50%. Specifi-
cally, 7 of those 22 patients had N2 disease pathologically in the
specimen. As well, we compared the survival of patients who un-
derwent mediastinoscopy and patients who had disease diagnosed
by radiographic criteria, and survival did not statistically differ be-
tween these groups.
Dr Darling. Did you consider analyzing the whole group with-
out those patients?
Dr Paul. Sure.We also did the analysis excluding all 22 patients
who had diagnoses based solely on radiographic criteria, and es-
sentially we came up with the same conclusions. Our multivariate
analysis showed age, extent of resection, and residual N2 as fac-
tors; however, the P value for one of them changed to be greater
than .05. So it was a trend as opposed to being significant.
Dr Darling. In light of the importance of the mediastinal down-
staging, do you have any recommendations for us in terms of
whether we should be restaging the mediastinum? Would you
not offer surgery to patients who have persistent N2 disease?
DrPaul.Our policy has been not to restage themediastinum, be-
cause we do offer resection to patients who have persistent N2 dis-
ease. We believe that a 20% 5-year survival is better than nothing.
Dr Robert J. Cerfolio (Birmingham, Ala). But you just showed
that they did poorly. Are you going to change your recommenda-
tions from your own data?
Dr Paul. It depends on what the alternative is. If they have no
viable alternative therapy that they can receive, we’re not going
to change.56 The Journal of Thoracic and Cardiovascular SurgeDr Mark J. Krasna (Towson, Md). Congratulations, Dr Paul,
on an excellent presentation, and congratulations to you and
your group for amazing mortality statistics.
I have a comment and a question. I think what you have done is
help us to refine further who are the patients we should operate on
after induction therapy. My personal bias, and that of Drs Cerfo-
lio, Weder, and Venuta, 3 other people in the room who presented
in the past year on either pneumonectomy or lobectomy, is that
chemotherapy and radiation together might give you a better path-
ologic response and might give you better long-term survival, but
I don’t think that’s the issue. You have done a very good job,
though, in showing us exactly what Dr Cerfolio pointed out.
That is, if you can determine up front that you have patients
with persistent positive nodes, don’t operate on them. If you
find out up front that there are patients who have other predictors
for poor long-term outcome, don’t operate on them. We should
only be operating on those patients for whom we can document
downstaging and who had a good response. So I think the ques-
tion of chemoradiotherapy versus chemotherapy would be inter-
esting, but the same issue comes up. You should really be
tackling those.
My question relates to, and I guess Dr Meyers needs to help us
statistically, I’m sure there is statistical error. You had only 1 death.
How could one death out of 27 pneumonectomies in the overall
pneumonectomies and lobectomies still have survived both univar-
iate and multivariate analysis to be an independent prognosticator?
I think there has got to be some other explanation.
Dr Paul. The numbers are small, and we ran the numbers in var-
ious different ways, and I think it’s a statistical thing that happens
when numbers are that small.
Dr Krasna. I would suggest that the last conclusion may not in
fact be upheld by that 1 death. I think there are enough con-
founders, although I can’t explain them. The conclusion that pneu-
monectomy in fact is a poor independent prognosticator, I don’t
know whether that is upheld by that 1 death.
Dr Altorki. The issue of operating on patients with residual N2
disease is obviously controversial. In reality, however, although
20% survival in such patients is not great, I don’t know that there
are many other options out there to treat patients who have persis-
tent N2 disease that is not responsive to chemotherapy. So I think at
the very least, we can all agree that the question is open for discus-
sion. If there were a clinical trial in which those patients could be
realistically enrolled, I think that would be ideal, but there isn’t,
and until there is you would have to decide whether a lobectomy
that can achieve an R0 resection with a 1% or 2%mortality is a rea-
sonable option. I would contend that it is.
Dr Cerfolio. Dr Altorki, if it was more than 1 station and re-
quired a pneumonectomy, do you agree that you wouldn’t do it?
Dr Altorki.Well, I think that the issue of multistation disease is
interesting, because it’s sometimes difficult to make that determi-
nation except intraoperatively.
Jean Deslauriers just told that he thought pneumonectomy is not
a great operation. I agree with that. But regardless of its physio-
logic impact on the patient, it is a marker of higher tumor burden.
At least in this study, the tumor bulk precluded treatment with
a sleeve lobectomy. So the idea that we’re going to somehow im-
prove survival for these patients by avoiding pneumonectomy and
doing sleeve lobectomy instead is an erroneous concept.ry c January 2011
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SDr Marcin Zielinski (Zakopane, Poland). You showed very
nicely that some patients who do not have downstaging still
have some chance for 5-year survival. Twenty percent is quite
a good number of patients who can be long-term survivors. But
the problem is determining which patients without downstaging
have a chance for 5-year survival. In my institution, our policy is
to restage these patients who are candidates for an operation
with transcervical extended mediastinal lymphadenectomy, and
the patients in whom we are able to completely resect the nodes
and the number of the metastatic nodes is not so large are the
ones for whom we propose resection. I think this is the group we
choose with the best prognosis.
Of the patients without downstaging, with persistent N2 nodes,
who are the best candidates for an operation, and who can expect
5-year survival? What is your policy?
Dr Paul. Well, first of all, I don’t think our study is powered
enough to answer that question. Our policy has been to offer resec-
tion to patients who are young and have good performance status,
as long as we think, at least preoperatively looking at the scans,
that we can do an adequate R0 resection, take out most of the nodal
stations through a thoracotomy. I think it’s a similar answer towhat
you’re alluding to, that you can give them a good cleanout of the
mediastinum by looking at the preoperative scans.
Dr Zielinski.But can you predict whowill be the long-term sur-
vivors?
Dr Paul. We don’t have the data to predict that.
Dr Frank C. Detterbeck (New Haven, Conn). Dr Paul, very
nice study. I think this was very helpful. On the other hand, there
are a couple pieces of data that are missing that I think would be
helpful. One is just to elucidate very carefully what your philoso-
phy was during this relatively long period. You have kind of said
you didn’t restage, anybody that looked reasonable you took to
the operating room, but it would be nice to know a little bit
more precisely what the philosophy was, so that we can interpret
a little bit better what that means. Another piece of data that would
be very interesting would be how many patients you ended up giv-
ing preoperative therapy to and then did not take to the operating
room, just like Rob [Dr Cerfolio] had told us about 2 years ago, I
think it was. I think that would help us kind of gauge how selective
or nonselective you were. And the third piece of data that I would
love to have would be, about those patients on whom you decided
not to operate and who didn’t have brain metastases or progressive
disease, how did they do? If your 20% is better than 5%, then that’s
very convincing. If those patients actually also had 20%, then, of
course, it’s different.
Dr Paul. Dr Detterbeck, those are excellent questions, and ac-
tually when we originally approached this project, that was one of
our aims, to see what happens to all those patients who had media-
stinoscopy, got induction therapy, and never made it to surgery.
Unfortunately, we get patients referred to us from all over the
city who come from outside oncologists, and often they go back
to those outside oncologists, and it’s very difficult for us to assess
actually what happened to them, what their survival was. That is an
excellent question, and we are exploring ways of trying to answer
it.
Dr Altorki. I think that’s an important question, and I think the
judgment regarding resectability is made at time zero. If the patient
is deemed to have a resectable tumor, then he or she gets 3 or 4 cy-The Journal of Thoracic and Ccles of chemotherapy. I personally have not seen many patients
progress from resectability to unresectability within that period.
Dr Paul DeLeyn (Leuven, Belgium). Thank you very much for
this presentation. I think that many centers indeed have patients
with persistent N2 disease who have a survival of 20% or 25%,
but I would like to stress that mostly this is among selected pa-
tients, patients who had all aims of restaging, patients who had
a good response on PETor CT. So probably there is some selection.
I have a few questions. Your complete resectability rate is very
high when you compare it to the literature. Can you give us your
definition of complete resectability? The highest lymph node,
was it positive, negative?
Dr Paul. The highest lymph node being negative, as well as the
bronchial margin being negative.
Dr DeLeyn. But this is very high.
Dr Paul. It’s a high R0 rate. I recognize that.
Dr DeLeyn. Patients with persistent N2, did they get adjuvant
radiotherapy?
Dr Paul. Patients with persistent N2, if they could tolerate ad-
juvant radiotherapy, did get it.
Dr DeLeyn. How many patients?
Dr Paul. I don’t remember off the top of my head. It’s in the ar-
ticle. It’s probably on the order of about 60%.
Dr DeLeyn. And now that we have endobronchial ultrasonog-
raphy or endoscopic ultrasonography for primary staging, is your
current practice still to do mediastinoscopy?
Dr Paul. Our current policy is that we do not restage these pa-
tients if they—
Dr DeLeyn. I know, but do you still do mediastinoscopy?
Dr Paul.We still do mediastinoscopy on patients who have sus-
pected N2 disease.
Dr Cerfolio. He wants to know whether you’re saving the me-
diastinoscopy until after the neoadjuvant. So you’re starting off
with endobronchial ultrasonography and endoscopic ultrasonogra-
phy and doing the mediastinoscopy second?
Dr Paul. We have not started doing that quite yet.
Dr Joe B. Putnam (Nashville, Tenn). I enjoyed your presenta-
tion and was intrigued by the number of patients who underwent an
operation versus the denominator of about 450 patients who were
treated. These procedures represent the ultimate in personalized
surgical care, in that these patients were highly selected by the in-
dividual surgeon as capable of tolerating the operation, with a high
likelihood of R0 resection, which you so clearly demonstrated. As
you mentioned, these operations were done by accomplished sur-
geons, in an excellent center, supported by an experienced multi-
disciplinary team before the operation and a talented
multispecialty team during the operation as well. So I think these
findings reflect to some extent the advantages that come from a fo-
cused expertise in this area within a single hospital and may not be
generalizable to hospitals broadly across the United States or inter-
nationally. Recognizing this personal approach, many patients
have undergone chemotherapy and radiation in varying amounts
and in various intervals between cessation of radiation and the
time they appear in my outpatient clinic ready to have their tumor
removed! Could you comment on the number of patients who had
therapy outside your institution who were then operated on and on
the interval between the induction chemoradiotherapy being con-
cluded and the time the operation was performed?ardiovascular Surgery c Volume 141, Number 1 57
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SDr Paul. There were approximately 12 patients basically had
their staging done at an outside institution and received chemo-
therapy. As for the interval, I’m not sure. Our general policy has
been to wait about 3 to 4 weeks after the last dose of chemotherapy
before operating.
Dr L. Penfield Faber (Chicago, Ill). I compliment you on an
outstanding series that corresponds to our approach to clinically
advanced lung cancer at the Rush University Medical Center.
I noted that you only had 2 complete pathologic responses. In
other words, only 2 were sterilized, yet you had 49% down-
staged. This is a very nice result of downstaging. On the other
hand, we know that series that use ‘‘chemo-beamo,’’ or chemo-
radiation, have 18% to 22% complete pathologic responses.
These patients have long-term survival of 50%. So, I suggest
your results might improve with chemoradiation rather than che-
motherapy alone.
Dr Paul.We have a few thoughts on that. One is that our rate of
nodal downstaging is similar to that which was published in the in-
tergroup trial, which is roughly around 52%. In terms of recur-58 The Journal of Thoracic and Cardiovascular Surgerences, in most cases the site of first recurrence was distant.
About 78% to 80% of the patients had distant disease as the site
of first recurrence. In terms of local recurrence, rates were about
10% in the pneumonectomy group and 12% in the lobectomy
group. Our thoughts are that we don’t see how adding preoperative
radiation is going to improve on those results. I think that’s a con-
troversial topic, however, and that’s just our take on it.
Dr Faber. Different strokes for different folks. I have one his-
torical comment. If you look very carefully at the picture of the
pneumonectomy specimen removed by Evarts Graham, you will
note that there were N2 nodes present. So it began on day 1. Resect
those N2 nodes.
Dr Dominique H. Grunenwald (Paris, France). Excellent pre-
sentation. There is a question raised regarding the role of postop-
erative radiotherapy in N2 disease, and there is a place for a large
clinical trial addressing this issue. That is what we are trying to do
in Europe actually at this time, but with very great difficulties re-
garding inclusion of the patients, because N2 disease that is oper-
ated on and completely resected is rare.ry c January 2011
